Greenwich Lifesciences Provides Clinical Updates On FLAMINGO-01

July 20 (Reuters) - Greenwich Lifesciences Inc GLSI.O:

• Greenwich Lifesciences provides clinical updates on FLAMINGO-01
• Greenwich Lifesciences - FLAMINGO-01 DSMB recommends study continue without modification in May 2026
• Greenwich Lifesciences - FLAMINGO-01 steering committee endorses study size increase and accelerated enrollment
• Greenwich Lifesciences - FLAMINGO-01 Phase 3 objectives met following FDA and EMA review
• Greenwich Lifesciences - Q2 2026 burn rate expected at $2 million; cash balance $8.90 million as of June 30, 2026

Source text: ID:nGNX6DWTPp

Further company coverage: GLSI.O